{
    "nctId": "NCT00078832",
    "briefTitle": "Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer",
    "officialTitle": "International Breast Cancer Intervention Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 3864,
    "primaryOutcomeMeasure": "Development of histologically confirmed breast cancer, both invasive and non-invasive with median follow-up at 5 years",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Meets at least 1 of the relative risk factors based on age as follows:\n\n  * 45 to 70 years of age:\n\n    * First-degree relative who developed breast cancer at \u2264 50 years of age\n    * First-degree relative who developed bilateral breast cancer\n    * Two or more first- or second-degree relatives who developed breast cancer or ovarian cancer\n\n      * Participants having both relatives who are second degree and on the opposite sides of the family must have at least one that was diagnosed at \u2264 50 years of age\n    * Nulliparous (or first birth at \u2265 30 years of age) and a first-degree relative who developed breast cancer\n    * Benign biopsy with proliferative disease and a first-degree relative who developed breast cancer\n    * Mammographic opacity covering at least 50% of the breast in the absence of hormone replacement therapy within the past 3 months\n  * 60 to 70 years of age:\n\n    * First-degree relative with breast cancer at any age\n    * Age at menopause \u2265 55 years\n    * Nulliparous or age at first birth \u2265 30 years\n  * 40 to 44 years of age:\n\n    * Two or more first- or second-degree relatives who developed breast cancer or ovarian cancer at \u2264 50 years of age\n    * First-degree relative with bilateral breast cancer who developed the first breast cancer at \u2264 50 years of age\n    * Nulliparous (or first birth at \u2265 30 years of age) and a first-degree relative who developed breast cancer at \u2264 40 years of age\n    * Benign biopsy with proliferative disease and a first-degree relative who developed breast cancer at \u2264 40 years of age\n* All age groups (40 to 70 ears of age) with a 10-year risk \\> 5% who do not fit into the above categories are allowed\n\n  * Clearly apparent family history AND/OR other risk factors indicating appropriate increased risk of breast cancer for age\n* The following prior breast conditions are allowed (for all age groups):\n\n  * Lobular carcinoma in situ\n  * Atypical ductal or lobular hyperplasia in a benign lesion\n  * Ductal carcinoma in-situ (DCIS), diagnosed within the past 6 months, and treated by mastectomy\n* No evidence of breast cancer on mammogram within the past year\n* Hormone receptor status:\n\n  * For patients with prior DCIS, estrogen- or progesterone-receptor status must have been positive\n\n    * Must have had greater than or equal to 5% positive cells\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 40 to 70\n\nSex\n\n* Female\n\nMenopausal status\n\n* Postmenopausal, defined as at least 1 of the following:\n\n  * Over 60 years of age\n  * Bilateral oophorectomy\n  * \u2264 60 years of age with a uterus and amenorrhea for at least 12 months\n  * \u2264 60 years of age without a uterus and with follicle-stimulating hormone levels \\> 30 IU/L\n\nPerformance status\n\n* Not specified\n\nLife expectancy\n\n* At least 10 years\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* Not specified\n\nRenal\n\n* Not specified\n\nOther\n\n* Psychologically and physically suitable to receive 5 years of anti-estrogen therapy\n* No cancer within the past 5 years except non-melanoma skin cancer or carcinoma in situ of the cervix\n* No evidence of osteoporosis or fragility fractures within the spine\n\n  * Participants with a T-score \\> minus 4 and no more than 2 fragility fractures are allowed\n* No concurrent severe disease that would place the participant at unusual risk or confound the results of the study\n* No other medical condition that would preclude the ability to receive the study treatment\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* Not specified\n\nEndocrine therapy\n\n* No prior tamoxifen, raloxifene, or other selective estrogen receptor modulator (SERM) use for more than 6 months in duration unless an IBIS-I participant (must have been off trial therapy for at least 5 years.\n* No concurrent tamoxifen, raloxifene, or other SERM\n* No concurrent estrogen-based hormone replacement therapy\n* No concurrent systemic estrogen replacement therapy, including vaginal estrogen preparations\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* See Disease Characteristics\n* No prior prophylactic mastectomy\n* No concurrent prophylactic mastectomy\n\nOther\n\n* More than 6 months since prior investigational drugs",
    "sex": "FEMALE",
    "minimumAge": "40 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}